Jazz, PharmaMar Grab Priority Review for Lurbinectedin in Small Cell Lung Cancer

The FDA granted priority review to PharmaMar and Jazz Pharmaceuticals’ lurbinectedin to treat patients with small cell lung cancer (SCLC) who have progressed after prior platinum-containing therapy.

The designation was based on positive results from a phase 2 clinical trial which evaluated the drug to treat relapsed SCLC. The trial enrolled 105 patients from 39 centers across Europe and the U.S.

PharmaMar and Jazz Pharmaceuticals entered into a licensing agreement for lurbinectedin, granting Jazz U.S. commercialization rights for the drug.